RUTISS-Diary and RUTISS-65 Study
Developing and Validating Two New Patient-Reported Outcome Measures of Recurrent Urinary Tract Infection Symptoms: A Symptoms Diary and Adapted Measure for Older Adults
調査の概要
状態
詳細な説明
400 million people globally each year are affected by Urinary Tract Infections (UTIs) (Yang et al., 2022), with annual recurrence ranging from 24-50% (Foxman, 2014). Recurrent UTI (rUTI), defined as at least two UTIs in six months or at least three in one year (Bonkat et al., 2020), negatively affects quality of life (Wagenlehner et al., 2018) and repeat treatment risks antimicrobial resistance (Ormeño et al., 2022). Standard urine culture may present results discrepant with symptoms (Harding et al., 2022), hence the urgent need for quantifiable rUTI Patient Reported Outcome Measures (PROMs). Measures exist for acute infection (e.g. cystitis (Alidjanov et al., 2018) but not rUTI. We recently developed, published and commercially licensed two rUTI PROMs (the Recurrent Urinary Tract Infection Symptom Scale; RUTISS (Newlands et al., 2023) and the Recurrent Urinary Tract Infection Impact Questionnaire; RUTIIQ; Newlands et al., 2023b). However, neither has been adapted for daily symptom tracking or tailored to the needs of older adults. As a result, there is no rapid assessment tool that individuals living with rUTI (or their healthcare professionals) to analyse how rUTI symptoms change daily or to suitably assess adults over 65 years. This study aims to develop, validate and pilot two PROMs: 1) an adaptation of the RUTISS in daily diary format (RUTISS-Diary); and 2) an adapted RUTISS measure adapted for observational reporting of rUTI symptoms in older adults (RUTISS-65).
To inform the items of the RUTISS-Diary and RUTISS-65, extensive multiphase, mixed-methods preparatory work has been completed to ensure the items are informed from both patient and clinician perspectives. Phase 1 comprised of one-to-one interviews conducted with clinical experts working with older adults experiencing recurrent urinary tract infections (inclusive of urology, microbiology and geriatrics, N = 10, completed, UoR ethics ref: 2025-039-KF). This was accompanied by a literature review specific to older adult experiences of rUTI and patient interviews with outpatient members of Live UTI Free (N = 20, completed, UoR ethics ref: 2024-071-KF). Phase 2 consisted of two-rounds of HCP expert panel Delphi-surveys (N = 11) and cognitive interviews with expert patients (N = 25) for refinement of the measures (completed, UoR ethics ref: 2025-039-KF). These first phases are complete, informing the items of the RUTISS-Diary and RUTISS-65. The present study therefore aims to test and validate these measures to ensure they are reliable and are able to detect meaningful change.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Katherine A Finlay, PhD, CPsychol
- 電話番号:0118 378 8523
- メール:katherine.finlay@reading.ac.uk
研究連絡先のバックアップ
- 名前:Lydia V Tidmarsh, PhD
- 電話番号:0118 378 8523
- メール:l.v.tidmarsh@reading.ac.uk
研究場所
-
-
-
Reading、イギリス
- Royal Berkshire NHS Foundation Trust
-
Reading、イギリス、RG6 6ET
- University of Reading
-
コンタクト:
- Katherine A Finlay, PhD, CPsychol
- 電話番号:0118 378 8523
- メール:katherine.finlay@reading.ac.uk
-
コンタクト:
- Lydia V Tidmarsh, PhD
- 電話番号:0118 378 8523
- メール:l.v.tidmarsh@reading.ac.uk
-
主任研究者:
- Bob Yang, FRCS (UROL), MBBS, BSC (HONS)
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion for RUTISS-Diary:
- Participants must be 18 years and older
- All participants must have native/bilingual or advanced fluency in English.
- Access to a computer/mobile device for survey completion.
- Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).
Inclusion for RUTISS- 65:
- Participants must be 65 years and older
- Access to a computer/mobile device for survey completion, paper copy available upon request.
- All participants must have native/bilingual or advanced fluency in English.
- Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).
Exclusion criteria (for RUTISS-Diary and RUTISS-65)
- Participants must not report a current diagnosis of interstitial cystitis (measured in demographics questionnaire).
- Symptoms of cognitive confusion or dementia.
- No active malignancy e.g. bladder or prostate cancer
- Participants must not report beginner or intermediate level fluency in English. Future work will be done to translate the PROMs into alternative languages.
- In addition to the interstitial cystitis exclusion question, participants will also be asked in the demographic questionnaire if they are pregnant or have an indwelling catheter or use intermittent self-catheterisation. Participants who report "yes" to either of these will be excluded from participation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
RUTISS-Diary (Cohort A)
All rUTI patients of any age
|
RUTISS-Diary
|
|
RUTISS-65 (Cohort B)
rUTI patients aged 65 years and over
|
RUTISS-Diary
RUTISS-65
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Test-retest reliability
時間枠:RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Primary outcome measures will include the test-retest reliability and construct validity of the instrument.
Test-retest reliability will be assessed by calculating intraclass correlation coefficients (ICCs) for each subscale at each time point.
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
|
Construct validity
時間枠:RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Construct validity will be examined using correlation analyses between the subscales of the study measures and relevant comparative measures.
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sensitivity to change
時間枠:RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
Secondary outcome measures will assess the responsiveness (sensitivity to change) of the RUTISSdiary and RUTISS-65 using both anchor-based and distribution-based approaches, in line with COSMIN recommendations for continuous outcome measures (COSMIN, 2019).
|
RUTISS-Diary: From day 1 to day 7 and day 1 to day 14. RUTISS-65: From day 1 to day 2.
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Katherine A Finlay, PhD, CPsychol、University of Reading
- 主任研究者:Bob Yang, FRCS (UROL), MBBS, BSC (HONS)、Royal Berkshire NHS Foundation Trust
出版物と役立つリンク
一般刊行物
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003. Epub 2013 Dec 8.
- Newlands AF, Roberts L, Maxwell K, Kramer M, Price JL, Finlay KA. Development and psychometric validation of a patient-reported outcome measure of recurrent urinary tract infection impact: the Recurrent UTI Impact Questionnaire. Qual Life Res. 2023 Jun;32(6):1745-1758. doi: 10.1007/s11136-023-03348-7. Epub 2023 Feb 6.
- Newlands AF, Kramer M, Roberts L, Maxwell K, Price JL, Finlay KA. Confirmatory structural validation and refinement of the Recurrent Urinary Tract Infection Symptom Scale. BJUI Compass. 2023 Oct 4;5(2):240-252. doi: 10.1002/bco2.297. eCollection 2024 Mar.
- Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FME. Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. Antibiotics (Basel). 2018 Jan 15;7(1):6. doi: 10.3390/antibiotics7010006.
- Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022 Mar 9;376:e068229. doi: 10.1136/bmj-2021-0068229.
- Ormeno MA, Ormeno MJ, Quispe AM, Arias-Linares MA, Linares E, Loza F, Ruiz J, Pons MJ. Recurrence of Urinary Tract Infections due to Escherichia coli and Its Association with Antimicrobial Resistance. Microb Drug Resist. 2022 Feb;28(2):185-190. doi: 10.1089/mdr.2021.0052. Epub 2021 Aug 27.
- Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):107-117. doi: 10.1080/14737167.2017.1359543. Epub 2017 Jul 31.
- Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 2022 Jul 27;10:888205. doi: 10.3389/fpubh.2022.888205. eCollection 2022.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-028-KF
- IRAS ID: 366353 (その他の助成金/資金番号:HRA and HCRW)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。